Madrigal Pharma (MDGL) Tops Q2 EPS by 38c

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($7.10), $0.38 better than the analyst estimate of ($7.48). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $4.25 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Vishay launches compact proximity sensor with 5 μA idle current
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41